{
  "id": "6413712a201352f04a00003e",
  "type": "list",
  "question": "The 1p19q co-deletion is associated with what types of tumors?",
  "ideal_answer": "Lower grade gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p19 codeletion) have a favorable outcome. diffuse glioma cases (grade 2 56; grade 3 62; grade 4 182) based on this cl",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26542540",
    "http://www.ncbi.nlm.nih.gov/pubmed/23689617",
    "http://www.ncbi.nlm.nih.gov/pubmed/31157866",
    "http://www.ncbi.nlm.nih.gov/pubmed/23681562",
    "http://www.ncbi.nlm.nih.gov/pubmed/34667950",
    "http://www.ncbi.nlm.nih.gov/pubmed/27090007",
    "http://www.ncbi.nlm.nih.gov/pubmed/26206478",
    "http://www.ncbi.nlm.nih.gov/pubmed/35114775",
    "http://www.ncbi.nlm.nih.gov/pubmed/20446099",
    "http://www.ncbi.nlm.nih.gov/pubmed/18710393",
    "http://www.ncbi.nlm.nih.gov/pubmed/30842562",
    "http://www.ncbi.nlm.nih.gov/pubmed/31370384",
    "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
    "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
    "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
    "http://www.ncbi.nlm.nih.gov/pubmed/32894375",
    "http://www.ncbi.nlm.nih.gov/pubmed/30849537",
    "http://www.ncbi.nlm.nih.gov/pubmed/32681084",
    "http://www.ncbi.nlm.nih.gov/pubmed/20035368",
    "http://www.ncbi.nlm.nih.gov/pubmed/23344797",
    "http://www.ncbi.nlm.nih.gov/pubmed/32020379",
    "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
    "http://www.ncbi.nlm.nih.gov/pubmed/29218432",
    "http://www.ncbi.nlm.nih.gov/pubmed/34125374",
    "http://www.ncbi.nlm.nih.gov/pubmed/24877111",
    "http://www.ncbi.nlm.nih.gov/pubmed/25277207",
    "http://www.ncbi.nlm.nih.gov/pubmed/29550880",
    "http://www.ncbi.nlm.nih.gov/pubmed/25636755",
    "http://www.ncbi.nlm.nih.gov/pubmed/29890994",
    "http://www.ncbi.nlm.nih.gov/pubmed/34268651",
    "http://www.ncbi.nlm.nih.gov/pubmed/32906679",
    "http://www.ncbi.nlm.nih.gov/pubmed/33361717",
    "http://www.ncbi.nlm.nih.gov/pubmed/33482430",
    "http://www.ncbi.nlm.nih.gov/pubmed/19624298",
    "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
    "http://www.ncbi.nlm.nih.gov/pubmed/32305004"
  ],
  "snippets": [
    {
      "text": "Lower grade gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/19 codeletion) have a favorable outcome. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32894375",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "diffuse glioma cases (grade 2, 56; grade 3, 62; grade 4, 182) based on this classification. Mutations in the isocitrate dehydrogenase (IDH) genes were common in lower grade glioma (LGG: grade2-3), and when combined with 1p/19q status,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34268651",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations, including IDH mutations, 1p19q co-deletion status and MGMT promoter methylation have been proven to be prognostic and predictive to response to treatment in gliomas. I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34667950",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oligodendroglioma, IDH-mutant and 1p/19q codeleted: 37;",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34268651",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32305004",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The presence of chromosome 1p/19q co-deletion is one of the hallmark required criteria for the diagnosis of oligodendroglioma, using the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32305004",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Descriptions in the literature of astrocytomas, primarily glioblastomas, demonstrating partial losses on one or the other chromosome have been described.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32305004",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oligodendroglial tumours (OT) are a heterogeneous group of gliomas. Three molecular subgroups are currently distinguished on the basis of the IDH mutation and 1p/19q co-deletion.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27090007",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " three subgroups within 1p/19q co-deleted tumours, associated with specific expression patterns of nervous system cell types: oligodendrocyte, oligodendrocyte precursor cell (OPC) and neuronal lineage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27090007",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "diffuse gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted/IDH mutant, intact 1p/19q/IDH mutant and IDH wild type.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29218432",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Co-deletion of 1p/19q is a hallmark of oligodendroglioma and predicts better survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32681084",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The second is that examinations for IDH mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32020379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Co-deletion of chromosome arms 1p and 19q, characteristic of oligodendroglial tumors, was recently found to be mediated by t(1;19)(q10;p10).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18710393",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results suggest that 1p19q loss and t(1;19) occur in a subset of EVN, and may be associated with aggressive histology in these tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18710393",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: Co-deletion of 1p and 19q marks a diffuse glioma subtype associated with relatively favorable overall survival; however, heterogeneous clinical outcomes are observed within this category.Methods: We assembled gene expression profiles and sample annotation of 374 glioma patients carrying th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "1p19q co-deletion is a chromosomal alteration associated with primary brain tumours of oligodendroglial histology.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Together with isocitrate dehydrogenase (IDH) mutation, co-deletion of 1p19q (1p19q codel) is a prerequisite for diagnosis of oligodendroglioma, making it imperative that histopathology laboratories introduce testing for 1p19q codel.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33361717",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To evaluate the prevalence of 1p19q co-deletion and t(1;19) in extraventricular neurocytomas (EVN), we studied tumors from 23 patients, including 13 females and 10 males (median age at diagnosis 34 years, range 2-76 years).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18710393",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The IDH-mutant and 1p/19q co-deletion (1p19q codel) provides significant diagnostic and prognostic value in lower-grade gliomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29550880",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25277207",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Whole arm 1p19q co-deletion was present in three cases from adolescent patients and 9p loss in 3, including one low-grade oligodendroglioma with CDKN2A homozygous deletion.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26206478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oligodendrogliomas (ODs) are the second most common malignant brain tumor and exhibit characteristic co-deletion of chromosomal arms 1p and 19q (co-deletion 1p/19q), which is associated with down-regulation of tumor suppressors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26542540",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oligodendrogliomas are primary human brain tumors with a characteristic 1p/19q co-deletion of important prognostic relevance, but little is known about the pathology of this chromosomal mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29890994",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It has been reported recently that oligodendroglial tumors arising in the insula rarely harbor co-deletions of chromosomes 1p and 19q, a molecular signature which is associated with a good prognosis and increased responsiveness to radiation and chemotherapy compared with tumors in which 1p and/or 19q is intact.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20035368",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31157866",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " We investigated a series of 1305 gliomas and showed that IDH mutation is almost constant in 1p19q codeleted tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24877111",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The study demonstrated that 1p/19q co-polysomy is a poor prognostic marker for glial tumor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30849537",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In the brain tumor, identification of molecular alterations, including 1p/19q co-deletion, is essential for accurate glial tumor classification.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30842562",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In conclusion, the expression profile of 1p19q genes is highly associated with the malignancy and prognosis of 1p/19q non-codel gliomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31157866",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " On the other hand, sequence studies have recently linked the CIC mutation and subsequent altered CIC expression to the 1p/19q co-deletion in oligodendroglial tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Anaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34125374",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Combined immunohistochemical analysis assessed by INA expression and/or the lack of CIC expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q state.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "or purity was found to be significantly decreased in high-risk IDH-mutant with 1p/19q co-deletion gliomas and IDH-wild-type glioblastomas but not in IDH-wild-type lower grade or IDH-mutant, non-co-deleted gliomas.Con",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "reatment strategy. However, there are still unanswered questions regarding whether upfront chemotherapy, omitting/deferring radiotherapy, in the desire to avoid late neurocognitive toxicity of radiotherapy should be the initial therapy for AO tumors with codeleted 1p19q, or whether temozolomide, an oral agent with a better toxicity profile, can be substituted for procarbazine, lomustine, and",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344797",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " results for 1p19q co-deletions (n\u2009=\u20099) or EGFR amplification (n\u2009=\u20098). Gliomas positive for 1p19q co-deletions did not have other frequently recurrent",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "uation. Data concerning low-grade gliomas were more controversial. Oligodendroglial tumors with 1p deletion or 1p19q codeletion seemed to have a bette",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the WHO glioma classification guidelines grade (glioblastoma versus lower-grade glioma), IDH mutation and 1p/19q co-deletion status play a central role as they are important markers for prognosis and optimal therapy planning.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33482430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We confirmed the high incidence (82%) of combined 1p19q deletion in LGOs and the feasibility of successful FISH testing in paraffin embedded specimens up to 10-years-old.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19624298",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "the 26 tumours, 6 oligodendrogliomas had 1p19q co-deletion and the remaining 3 oligodendrogliomas showed no co-deletion. Th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35114775",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The authors describe a case wherein a 1p19q deletion in a disseminated tumor with mixed immunohistochemical features of oligodendroglioma and neurocytoma was encountered and treated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The lack of CIC expression was detected in 13 cases (68\u00a0%) of oligodendroglial tumors with the 1p/19q co-deletion, and in only 1 case of oligodendroglial tumors without the 1p/19q co-deletion (5\u00a0%, P\u00a0<\u00a00.0001).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "1p/19q codeletion, which leads to the abnormal expression of 1p19q genes in oligodendroglioma, is associated with chemosensitivity and favorable prognosis. Here, we aimed to explore the clinical implications of 1p19q gene expression in 1p/19q non-codel gliomas. We analyzed expression of 1p19q genes in 668 1p/19q non-codel gliomas obtained from The Cancer Genome Atlas (n = 447) and the Chinese Glioma Genome Atlas (n = 221) for training and validation, respectively. The express",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31157866",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oligodendroglial tumors (OTs) are primary brain tumors that show variable clinical and biological behavior. The 1p/19q codeletion is frequent in these tumors, indicating a better prognosis and/or treatment response. Recently, the prognostically favorable CpG island methylator phenotype (CIMP) in gliomas (G-CIMP+) was associated with mutations in the isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 (IDH) genes, as opposed to G-CIMP- tumors, highlighting the relevance of epi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689617",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Anaplastic gliomas represent a heterogeneous group of primary high-grade brain tumors, and the optimal postoperative treatment remains controversial. In this report, we present our institutional data on the clinical outcomes of radiation therapy (RT) plus temozolomide (RT + TMZ) for anaplastic gliomas, stratified by histology and 1p/19q codeletion.METHODS AND MATERIALS: A singl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25636755",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oligodendroglioma (OD) is a subtype of glioma occurring in the central nervous system. The 1p/19q codeletion is a prognostic marker of OD with an isocitrate dehydrogenase (IDH) mutation and is associated with a clinically favorable",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32906679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: Co-deletion of 1p and 19q marks a diffuse glioma subtype associated with relatively favorable overall survival; however, heterogeneous clinical outcomes are observed within th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "IDH1/2 mutations and 1p/19q codeletion occur frequently in anaplastic gliomas and are prognostic factors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681562",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A total of 124 cases of diffuse gliomas were collected, and tissue microarray blocks were made. IDH1 mutation was tested using immunohistochemistry, and 1p/19q co-deletion status was examined using fluorescence in situ hybridization analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31370384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective stud",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32681084",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ultigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Glial tumors are malignant brain tumors that arise from glial cells of brain or spine and have genetic aberrations in their genome. 1p/19q co-deletion is associated with increased",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30849537",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We aimed to explore the expression of Olig2 in different glial neoplasms and to investigate if diffuse Olig2 expression can replace 1p19q co-deletion for the diagnosis of oligodendroglioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35114775",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "oligodendrocyte transcriptional factor-2 (Olig2) be used as an alternative for 1p/19q co-deletions to distinguish oligodendrogliomas from other glial neoplasms",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35114775",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The 1p deletions and 1p19q codeletion mean rates were respectively 65.4 and 63.3% in oligodendrogliomas, 28.7 and 21.6% in oligoastrocytomas, 13.2 and 7.5% in astrocytomas, 11.6 and 2.9% in glioblastoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The presence of 1p deletion and 1p19q codeletion were strongly correlated with the histological diagnosis corresponding to oligodendroglioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Losses of chromosomes 1p and 19q are deemed correlated with diagnosis of oligodendroglioma, higher chemosensitivity and better prognosis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "eptomeningeal dissemination of a pediatric neoplasm with 1p19q deletion showing mixed immunohistochemical features of an oligodendroglioma and neurocytoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446099",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "eptomeningeal dissemination of an oligodendroglioma is rarely reported in the neurosurgical literature, especially in cases with a classical 1p19q deletion",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "etrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19624298",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25636755",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "1p/19q Codeletion in Oligodendroglioma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32906679",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681562",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "astrocytomas, glioblastoma, Oligodendrogliomas, oligodendrial diffuse glioma chromosome 1p/19q co-deleted/IDH mutant, oligodendrocyte precursor oligodendriogial gliomas, neuronal linage oligodendrogiiomas, neurocytoma"
}